Search Results

adults with cancer who may experience poor outcomes. Although older patients with cancer represent an increasing and heterogeneous population with diverse needs, little research has sought to identify those at risk of experiencing high symptom burden or

Background The prevalence of distress, anxiety, and depressive symptoms has not been assessed by standard measures in patients with BCR-ABL–negative myeloproliferative neoplasms (MPNs). This is perhaps surprising given the large symptom burden

those on intravenous treatment, 10 , 11 which could negatively influence adherence, 12 it is important to understand patients’ symptom burden, adherence, and distress in a clinical setting. Although oral therapy is thought to impair QoL less than

Myeloproliferative neoplasms (MPNs) are a unique form of hematologic malignancy that are characterized by an elevated rate of physical symptom burden along a progressive and chronic disease trajectory. 1 Patients with MPNs often report high

addition, more clarity now exists regarding the impact of the MPN symptom burden, attributed partly to cytokine excess, splenomegaly, hyperviscosity (PV), thrombotic complications, and cytopenias (MF). In some patients with MF, the impairment in quality of

provided molecular targets for drug development in both PV and ET. The primary goals of treatment for MPNs are to reduce the risk of thrombosis and alleviate systemic symptom burden (eg, fatigue, pruritus, microvascular symptoms, symptomatic splenomegaly

add to the complexity of caring for older adults with cancer. Older patients experience unique concerns related to their physical function, comorbid conditions, and medication management (ie, geriatric-specific issues), as well as their symptom burden

. Integration in these ways is of particular importance in CCMS patient populations who demonstrate a “complex” symptom burden, often influenced by a number of biopsychosocial concerns. 6 – 8 It allows for better coordinated interprofessional approaches and

and previous literature on EoL preferences, 15 – 19 we hypothesized that preferred PoD and the stability of that preference will be associated with time-varying factors, including patients’ psychologic distress, symptom burden, quality of life (QoL

anxiety risk screening subscales), (2) symptom burden, (3) body and healthy lifestyle, (4) healthcare team communication, and (5) relationships. This study developed a short form of CSS and examined its psychometric properties. Methods: 2,379 cancer